Outcome of Board Meeting held today dated August 13, 2025
Awaiting price reaction for this filing.
Uniworth International Ltd's board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). The company reported zero revenue from operations and zero other income for the quarter, resulting in a standalone net loss of Rs. 38.81 lakhs and a consolidated net loss of Rs. 40.42 lakhs (improved from Rs. 157.73 lakhs loss in Q1 FY25, largely because the subsidiary Uniworth Biotech reported nil revenue and nil loss). Finance costs stood at Rs. 38.25 lakhs for the quarter despite no business activity. The company explicitly disclosed that there have been 'no business activities in the Company since long,' has not recognized deferred tax assets due to uncertainty of future profits, and has applied to the RBI for extensions/settlements of overdue bills.
This is a serious red flag for shareholders — the company is essentially dormant with no revenue, recurring losses, pending RBI settlements, and large unprovided receivables (Rs. 3,010+ lakhs) and unprovided bank interest, all pointing to going concern risk and very limited near-term recovery prospects for the stock.